Paper Details

  1. Home
  2. Paper Details

Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis.

Author: AluochJ A, Babu SwaiO, DarbyshireJ H, EdwardsE A, GithuiW A, NunnA J, Thiong'oR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 226 patients with pulmonary tuberculosis who failed primary chemotherapy due to drug-resistant strains found that a 9-month regimen of rifampicin and ethambutol was more effective than a 6-month regimen in preventing relapses, particularly for patients with resistance to both isoniazid and streptomycin.
Paper Details　
Original Abstract of the Article :
Patients with pulmonary tuberculosis who were failures of primary chemotherapy with strains resistant to isoniazid or to isoniazid and streptomycin were allocated at random to receive a regimen of rifampicin and ethambutol for 6 (4RE) or 9 months (7RE), supplemented in both treatment series by strep...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0041-3879(88)90035-9

データ提供：米国国立医学図書館（NLM）

Tackling Isoniazid-Resistant Tuberculosis: A Controlled Clinical Trial

Tuberculosis (TB) is a persistent foe, and the rise of drug-resistant strains is a major challenge in the fight against this disease. This research focuses on a crucial aspect of TB treatment - tackling strains resistant to isoniazid, a key antibiotic used to treat TB. It is like a desert battle against a resilient enemy - the study seeks to find the most effective weapon to combat the resistant strains.

A Battle for Time: Shortening Treatment Duration

The study aimed to determine whether a shorter treatment regimen of 6 months, compared to 9 months, would be equally effective in treating patients with isoniazid-resistant TB. The results showed that both treatment durations were successful in most cases. However, the study found that patients with resistance to both isoniazid and streptomycin were more likely to relapse with the shorter regimen, highlighting the importance of tailoring treatment to the specific strain of TB. The study emphasizes the need to find the right balance between treatment duration and effectiveness, like strategically navigating a desert to reach your destination.

Understanding the Dynamics of Resistance

This research provides valuable insights into the complex dynamics of drug resistance in TB. It demonstrates the importance of carefully evaluating treatment regimens and adapting them to individual patients. The study offers a critical perspective on the need for continued research into new drug regimens and treatments for drug-resistant TB. It's a reminder that the battle against TB requires constant vigilance and innovation.

Dr. Camel's Conclusion

The findings of this study demonstrate that the fight against TB requires a nuanced approach, considering both the individual patient and the specific strain of bacteria. While the study showcases the effectiveness of both short and long treatment regimens in most cases, it emphasizes the need to carefully assess the risk of relapse, especially in patients with multi-drug resistant TB. The desert of TB is vast and complex, but this study provides a beacon of hope for finding more effective and targeted treatments.

Date :
  1. Date Completed 1988-11-23
  2. Date Revised 2019-09-08
Further Info :

Pubmed ID

3051607

DOI: Digital Object Identifier

10.1016/0041-3879(88)90035-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.